Back to today’s briefing

Story perspectives

FDA Eases Restrictions on CAR T-Cell Therapies

6/28/2025

45 7

Summary

Story summary

The FDA has made a significant change by updating the labels for liso-cel and ide-cel, slashing driving restrictions from 8 weeks to just 2, and proximity requirements from 4 weeks to 2 after treatment. This move is set to enhance access to CAR T-cell therapies for lymphoma and multiple myeloma patients, breaking down barriers to better care.

1 of 1

Story summary

The FDA has made a significant change by updating the labels for liso-cel and ide-cel, slashing driving restrictions from 8 weeks to just 2, and proximity requirements from 4 weeks to 2 after treatment. This move is set to enhance access to CAR T-cell therapies for lymphoma and multiple myeloma patients, breaking down barriers to better care.